Throughout the screening, it was observed that the anti-AD drugs, including Lupron, Nilotinib, Telmisartan, CORT108297, neflamapimod, and bromocriptine, displayed a better binding affinity with the LPARs, the SPIKE, and hinder LPARs-SPIKE protein complex than the standard compounds. Here, CHMP5 is linked to Alzheimer disease.